Warnex Completes the Sale of its Bioanalytical Services Division and Implements the Consolidation of its Common Shares

LAVAL, QUEBEC–(Marketwire – Dec. 11, 2012) – Warnex Inc. (TSX VENTURE:WNX) ("Warnex" or the "Corporation") is pleased to report that it has successfully completed the previously announced sale (the "Transaction") of its Bioanalytical Services division to Biotrial Research S.A.S., a privately-owned contract research organization headquartered in Rennes, France. A special resolution approving the Transaction was adopted with the support of over 96.3% of the votes cast by shareholders at the annual and special meeting of shareholders of the Corporation held on December 10, 2012 (the "Shareholders' Meeting").

"With the completion of this transaction, the Board will explore possible strategic alternatives for Warnex's remaining assets, which consist primarily of cash and receivables, for the benefit of all our shareholders," said Michael Singer, Chairman of the Board of Directors of the Corporation. "We expect to quickly identify opportunities, if any, which may range from a possible wind-up of Warnex and cash distribution to shareholders to a variety of possible mergers and acquisitions alternatives. We will report back to our shareholders as expeditiously as possible."

As a result of the closing of the Transaction, the listing of Warnex's common shares (the "Common Shares") is expected to be transferred from the TSX Venture Exchange to the NEX. Further details with respect to the transfer of the Common Shares to the NEX will be announced by the Corporation in due course.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.